reports
Six Directors bought 219,998 shares at 0.750USD.
Six Directors at Bioamber Inc bought 219,998 shares at 0.750USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadli...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...
BIOA Investors: GPM Reminds Investors of the May 17 Deadline in the Cl...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 t...
The Law Offices of Howard G. Smith Announces the Filing of a Securitie...
BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 to file a lead plaintiff motion. Investors suffering l...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class ...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) concerning possible violations of federal securities laws. Investors who purchased shares (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017 inclusive (the “Class Period”), should contact the firm prior to the May 17, 2017 lead plaintiff...
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class...
IRVINE, Calif.--(BUSINESS WIRE)-- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA). Investors who purchased or otherwise acquired BioAmber shares between January 23, 2017 and March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 17, 2017 lead plaintiff deadline. If you purchased shares of BioAmber during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 ...
BIOA LOSS NOTICE: Rosen Law Firm Reminds BioAmber Inc. Investors of Im...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of BioAmber Inc. securities (NYSE:BIOA): (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) publicly traded on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”) of the important May 17, 2017 lead plaintiff deadline in the first class action filed by the Rosen Law Firm. The lawsuit seeks to recover damages for BioAmber in...
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsui...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm announces a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA). Investors who purchased or otherwise acquired BioAmber shares between January 23, 2017 and March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 17, 2017 lead plaintiff deadline. To participate in this class action lawsuit, click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-...
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Aga...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of BioAmber Inc. securities (NYSE:BIOA): (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) publicly traded on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for BioAmber investors under the federal securities laws. ...
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Cla...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of BioAmber Inc. (NYSE: BIOA) resulting from allegations that BioAmber may have issued materially misleading business information to the investing public. On March 16, 2017, BioAmber during after hours trading announced disappointing financial results for the 2016 fiscal year, missing its previously issued revenue guidance by $1.3 million. On an earnings conf...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.